Contrasting 908 Devices (MASS) and Its Peers

908 Devices (NASDAQ:MASS) is one of 377 publicly-traded companies in the “Electronic Equipment, Instruments & Components” industry, but how does it contrast to its competitors? We will compare 908 Devices to related businesses based on the strength of its profitability, analyst recommendations, earnings, risk, dividends, institutional ownership and valuation.

Risk & Volatility

908 Devices has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, 908 Devices’ competitors have a beta of 1.41, suggesting that their average share price is 41% more volatile than the S&P 500.

Valuation and Earnings

This table compares 908 Devices and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
908 Devices	$60.84 million	N/A	-13.34
908 Devices Competitors	$1.13 billion	$82.84 million	0.52

908 Devices’ competitors have higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares 908 Devices and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
908 Devices	N/A	N/A	N/A
908 Devices Competitors	-76.74%	-39.07%	-11.96%

Insider and Institutional Ownership

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Electronic Equipment, Instruments & Components” companies are owned by institutional investors. 28.2% of 908 Devices shares are owned by insiders. Comparatively, 16.3% of shares of all “Electronic Equipment, Instruments & Components” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for 908 Devices and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1	0	3	0	2.50
908 Devices Competitors	2044	7576	10369	649	2.47

908 Devices presently has a consensus price target of $12.83, suggesting a potential upside of 1.29%. As a group, “Electronic Equipment, Instruments & Components” companies have a potential upside of 31.02%. Given 908 Devices’ competitors higher probable upside, analysts clearly believe 908 Devices has less favorable growth aspects than its competitors.

Summary

908 Devices beats its competitors on 7 of the 12 factors compared.

About 908 Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.